Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes
Authors
Keywords
Metformin, Fasting Plasma Glucose, Triple Therapy, Sitagliptin, Vildagliptin
Journal
CLINICAL PHARMACOKINETICS
Volume 56, Issue 7, Pages 703-718
Publisher
Springer Nature
Online
2016-12-30
DOI
10.1007/s40262-016-0498-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes
- (2016) Xueying Tan et al. ANNALES D ENDOCRINOLOGIE
- Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study
- (2016) Blisse Vakkalagadda et al. CLINICAL THERAPEUTICS
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
- (2016) André J. Scheen DIABETES & METABOLISM
- Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
- (2016) H. W. Rodbard et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
- (2016) Naveed Sattar et al. DIABETOLOGIA
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY
- (2016) Alan J. Garber et al. Endocrine Practice
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
- (2016) André J. Scheen Expert Opinion on Drug Metabolism & Toxicology
- Time for reconciliation between cardiologists and diabetologists
- (2016) André J. Scheen Nature Reviews Cardiology
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- (2016) Ling Li et al. BMJ-British Medical Journal
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- (2016) Ling Li et al. BMJ-British Medical Journal
- Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
- (2015) Takashi Sasaki et al. ADVANCES IN THERAPY
- Correction
- (2015) CIRCULATION
- Teneligliptin: A Review in Type 2 Diabetes
- (2015) Lesley J. Scott CLINICAL DRUG INVESTIGATION
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) André J. Scheen CLINICAL PHARMACOKINETICS
- Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin
- (2015) Ronnie Aronson CURRENT MEDICAL RESEARCH AND OPINION
- Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
- (2015) Stephan Matthaei et al. DIABETES CARE
- Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
- (2015) Chantal Mathieu et al. DIABETES CARE
- Where Does Combination Therapy With an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes?
- (2015) Muhammad Abdul-Ghani DIABETES CARE
- Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
- (2015) Andrew Lewin et al. DIABETES CARE
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
- (2015) Ralph A. DeFronzo et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes
- (2015) M. D. Sharma DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
- (2015) G. Fulcher et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2015) Silvio E. Inzucchi et al. DIABETOLOGIA
- Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
- (2015) Esther S. Kim et al. DRUGS
- SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
- (2015) André J. Scheen Expert Opinion On Drug Safety
- Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
- (2015) André J Scheen Expert Opinion On Drug Safety
- Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes
- (2015) David M Williams et al. EXPERT OPINION ON PHARMACOTHERAPY
- Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
- (2015) C Triplitt et al. EXPERT OPINION ON PHARMACOTHERAPY
- Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies
- (2015) Takashi Kadowaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option
- (2015) V. Woo INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
- (2015) Robert M. Guthrie POSTGRADUATE MEDICINE
- Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
- (2015) Yutaka Seino et al. Journal of Diabetes Investigation
- Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin
- (2014) Takeshi Kadokura et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
- (2014) A.J. Scheen et al. DIABETES & METABOLISM
- Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
- (2014) Julio Rosenstock et al. DIABETES CARE
- Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2014) Greg L. Plosker DRUGS
- Tofogliflozin: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Luseogliflozin: First Global Approval
- (2014) Anthony Markham et al. DRUGS
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2014) Greg L. Plosker DRUGS
- Postprandial Dynamics of Plasma Glucose, Insulin, and Glucagon in Patients with Type 2 Diabetes Treated with Saxagliptin Plus Dapagliflozin Add-On to Metformin Therapy
- (2014) Lars Hansen et al. Endocrine Practice
- Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease
- (2014) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
- (2014) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials
- (2014) Yukio Tanizawa et al. EXPERT OPINION ON PHARMACOTHERAPY
- A review of gliptins for 2014
- (2014) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
- (2014) Nobuya Inagaki et al. Journal of Diabetes Investigation
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers
- (2013) Christian Friedrich et al. CLINICAL THERAPEUTICS
- Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
- (2013) Serge A. Jabbour et al. DIABETES CARE
- Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers
- (2012) Tobias Brand et al. ADVANCES IN THERAPY
- Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin
- (2012) David W. Boulton et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Larry K. Golightly et al. CLINICAL PHARMACOKINETICS
- No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects
- (2012) R. A. Smulders et al. DIABETES OBESITY & METABOLISM
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
- (2010) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started